Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Giant Biogene Holding Co. Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.11B | 5.54B | 3.52B | 2.36B | 1.55B | 1.19B |
| Gross Profit | 5.00B | 4.55B | 2.95B | 2.00B | 1.35B | 1.01B |
| EBITDA | 2.60B | 2.31B | 1.78B | 1.21B | 933.64M | 826.02M |
| Net Income | 2.26B | 2.06B | 1.45B | 1.00B | 828.13M | 826.45M |
Balance Sheet | ||||||
| Total Assets | 11.29B | 8.04B | 4.97B | 3.14B | 7.88B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 8.86B | 5.86B | 3.78B | 2.20B | 7.26B | 1.96B |
| Total Debt | 6.95M | 6.71M | 2.73M | 2.59M | 0.00 | 0.00 |
| Total Liabilities | 2.10B | 918.14M | 602.03M | 301.19M | 6.86B | 2.19B |
| Stockholders Equity | 9.18B | 7.11B | 4.36B | 2.83B | 1.02B | 458.00M |
Cash Flow | ||||||
| Free Cash Flow | 1.47B | 1.79B | 1.42B | 778.39M | 581.21M | 757.79M |
| Operating Cash Flow | 1.83B | 2.04B | 1.65B | 931.64M | 692.40M | 834.12M |
| Investing Cash Flow | -688.87M | -1.11B | -527.28M | -858.74M | 1.56B | -521.12M |
| Financing Cash Flow | 1.25B | 582.95M | 51.81M | -5.79B | 4.48B | -17.52M |
Giant Biogene Holding Co. Ltd. Technical Analysis
Giant Biogene Holding Co. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$3.04B | 14.31 | 6.65% | 5.80% | 9.72% | -10.15% | |
73 Outperform | $32.17B | 13.02 | 10.69% | 5.46% | -3.48% | -24.11% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | HK$33.94B | 33.57 | 39.62% | 2.63% | 20.78% | 18.37% | |
61 Neutral | HK$38.58B | 15.33 | 29.64% | 1.73% | 36.70% | 22.26% | |
43 Neutral | HK$17.00B | -29.93 | -6.08% | 4.96% | 2.79% | -170.67% | |
41 Neutral | $1.08B | -17.36 | -12.38% | ― | 39.29% | -71.82% |
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene Holding Co., Ltd, a company incorporated in the Cayman Islands, announced a voluntary increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd. Juzi Holding has purchased a total of 4,226,600 shares, amounting to approximately HK$200.2 million, to demonstrate confidence in the company’s future development and to promote sustainable growth. This move increases Juzi Holding’s stake to 54.66% of the total issued shares, signaling a strong commitment to the company’s long-term success and potentially impacting market perceptions positively.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced that its subsidiary, Shaanxi Giant Biotechnology Co., Ltd., has received approval from the China National Medical Products Administration for its new product, Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers. This product, the first of its kind in China, is designed for facial dermal tissue filling to correct dynamic wrinkles. The approval highlights the company’s technological competitiveness and expands its product portfolio, positioning it for growth in the skin rejuvenation market. The company plans to leverage its existing brands and channels to launch and promote the product, reinforcing its leadership in the health and beauty industry.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$58.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd, a company incorporated in the Cayman Islands, announced an increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd. Juzi Holding has purchased a total of 3,666,600 shares, amounting to approximately HK$178.4 million, demonstrating confidence in the company’s future development. This move is aimed at promoting sustainable growth and safeguarding public investors’ interests, with Juzi Holding now holding 54.61% of the total issued shares.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$58.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd, a company incorporated in the Cayman Islands, announced a voluntary increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd. Juzi Holding has purchased 760,000 shares of the company for HK$31.9 million, raising its total shareholding to 54.56% of the company’s issued shares. This move is intended to demonstrate confidence in the company’s future development and to promote its sustainable growth. The increase in shareholding is expected to safeguard the interests of public investors and Juzi Holding may further increase its stake, depending on market conditions and regulatory requirements.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$58.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced that its controlling shareholder, Juzi Holding Co., Ltd, has increased its shareholding by purchasing 1,150,000 shares, amounting to approximately HK$62.9 million. This move reflects Juzi Holding’s strong confidence in the company’s future development and aims to promote sustainable growth and stability.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$58.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced an increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd, as a demonstration of confidence in the company’s future development. Juzi Holding has purchased 2,006,600 shares, amounting to approximately HK$105.6 million, raising its total ownership to 54.45% of the company’s issued shares. This move is intended to promote sustainable growth and protect public investor interests, with potential further share purchases depending on market conditions.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced its interim results for the six months ending June 30, 2025, reporting a significant increase in financial performance compared to the previous year. The company achieved a 22.5% increase in revenue, a 21.5% rise in gross profit, and a 20.6% growth in net profit. These results reflect the company’s robust operational strategies and market positioning, indicating a positive outlook for stakeholders and reinforcing its competitive stance in the biotechnology sector.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd., a company incorporated in the Cayman Islands, has announced the establishment of a Nomination Committee. This committee, composed mainly of independent non-executive directors, will be responsible for reviewing the board’s structure, identifying potential board members, and assessing the independence of directors. The move aims to enhance corporate governance and align the board’s composition with the company’s strategic goals.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd has announced the composition of its board of directors and their respective roles within the company. The board includes both executive and independent non-executive directors, with various members serving on key committees such as the Audit, Nomination, Remuneration, and Corporate Governance Committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes within Giant Biogene.
The most recent analyst rating on (HK:2367) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd has announced a board meeting scheduled for August 27, 2025, to review and approve the interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.